Horizon Pharma (HZNP) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Horizon Pharma plc Announces Second-Quarter 2016 Financial Results
August 8, 2016 7:00 AM EDT-- Second-Quarter 2016 Record Net Sales of $257.4 Million, Up 49 Percent ---- Second-Quarter 2016 GAAP Net Income of $15.0 Million; Adjusted EBITDA of $121.1 Million ---- Confirms Full-Year 2016 Net Sales Guidance of $1.025 to $1.050 Billion and Full-Year 2016 Adjusted EBITDA Guidance of $495 to $510 Million --
DUBLIN, Ireland, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its second-quarter 2016 financial results today and confirmed its full-year 2016 net... More
